TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 12/07/22

Summary Strong top-line growth exhibited in FY22. Building regulatory and clinical momentum around its core offerings, with the bulk of the portfolio up double digits this year. Technicals, valuations equally as supportive for upside capture. Rate buy, FY23 price objective $32.4...

Summary My portfolio, built specifically for my retirement ~20+ years from now, invested a new large position in a beaten down big tech stock. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a...

Takeda Pharmaceutical Company Limited (TAK) Q2 2022 Results Conference Call October 27, 2022 5:30 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andrew Plump - President, R&D Costa Saroukos - CFO Ramona Sequeira - P...

Summary The backbone of the company is Relugolix, a product in a platform already approved in three indications and planned to be investigated in additional indications. Relugolix has the potential to become the new standard of care in each indication and to generate billions in s...

Summary With KalVista's KVD824 off the market, Orladeyo will enjoy a stronger market presence since it was the first oral treatment for the HAE disorder after its approval in December 2020. BioCryst announced at the end of August 2022 that the FDA had granted orphan drug designati...

Summary Takeda has a dividend yield of 5.26%. It represents only 28% of free cash flow. Takeda is undervalued by nearly 70%. The reduction in revenues due to the patent expiration of VYVANSE will be equaled mainly by the growth of TAKHZYRO and ENTYVIO. The company is makin...

Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida established a deal with Roche for allogeneic therapies targeting hematological malignancie...

My portfolio, built specifically for my retirement ~20+ years from now, benefits from a surprise Petrobras gift. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retirement egg. A po...

Takeda Pharmaceutical Company Limited (TAK) Q1 2022 Results Conference Call July 28, 2022 06:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - President, R&D Costa Saroukos - CFO Masato Iwasaki - Japan ...